Process for preparing azabicyclic compounds

    公开(公告)号:NZ598277A

    公开(公告)日:2014-03-28

    申请号:NZ59827710

    申请日:2010-09-17

    Applicant: VERTEX PHARMA

    Abstract: 598277 The present disclosure relates to a process for preparing azabicyclic compounds that are useful intermediates for synthesizing pharmaceutical compounds or salts thereof. The process comprises contacting trans-4-aminocyclohexanol with Boc anhydride to produce a compound of formula A, contacting a compound of formula A with methanesulfonic acid to produce a compound of formula B contacting a compound of formula B with trifluoroacetic acid to produce a compound of formula C and contacting a compound of formula C with hydroxide to produce a compound of formula 7.

    Proceso para preparar compuestos azabicíclicos

    公开(公告)号:ES2540810T3

    公开(公告)日:2015-07-13

    申请号:ES10757544

    申请日:2010-09-17

    Applicant: VERTEX PHARMA

    Abstract: Un proceso para preparar el Compuesto 7.**Fórmula** o una sal farmacéuticamente aceptable del mismo, que comprende poner en contacto trans-4-aminociclohexanol con anhídrido Boc para producir un compuesto de fórmula A**Fórmula** poner en contacto un compuesto de fórmula A con cloruro de metanosulfonilo para producir un compuesto de fórmula B**Fórmula** poner en contacto un compuesto de fórmula B con ácido trifluoroacético para producir un compuesto de fórmula C**Fórmula** y poner en contacto un compuesto de fórmula C con hidróxido para producir un compuesto de fórmula 7.

    Process for preparing modulators of cystic fibrosis transmembrane conductance regulator

    公开(公告)号:NZ600172A

    公开(公告)日:2014-07-25

    申请号:NZ60017210

    申请日:2010-10-21

    Applicant: VERTEX PHARMA

    Abstract: Disclosed herein is a process for producing the hydrochloride salt of Compound 1 having solid Form A-HCl comprising: (a) reacting Compound 2 with the hydrochloride salt of Formula 3 (3-HCl) in the presence of a coupling agent, a base, and a polar aprotic solvent; wherein the coupling agent is selected from the group consisting of 2-chloro-1,3-dimethyl-2-imidazolium tetrafluoroborate, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 2-chloro-4,6-dimethoxy-1,3,5-triazine, 1-H-benzotriazolium-1-[bis(dimethyl amino)methylene]-5-chlorohexafluorophosphate (HCTU), 2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate (RA TU), 1-hydroxybenzotriazole (HOBT)/ 1-(3-(dimethylamino)propyl)-3-ethyl-carbodiimide hydrochloride (EDCl), and propane phosphonic anhydride; wherein the base is selected from the group consisting of K2CO3, Et3N, N-methylmorpholine (NMM), pyridine, and diisopropylethyl amine (DIEA); and wherein the polar aprotic solvent is selected from the group consisting of ethyl acetate, isopropyl acetate, tetrahydrofuran, methylethyl ketone, N-Methyl-2-pyrrolidone, acetonitrile, N,N-dimethyl formamide, and 2- methyltetrahydrofuran; and (b) treating a mixture comprising the product of step (a) with HCl; wherein step (a) is performed at a reaction temperature that is maintained between 15°C and 70°C.

Patent Agency Ranking